vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 39.2%, a 26.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 16.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 17.3%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
SCYX vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $26.9M |
| Net Profit | $12.3M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 50.0% |
| Net Margin | 65.7% | 39.2% |
| Revenue YoY | 1808.5% | 16.6% |
| Net Profit YoY | 376.5% | 34.8% |
| EPS (diluted) | $0.25 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $18.6M | $24.2M | ||
| Q3 25 | $334.0K | $25.0M | ||
| Q2 25 | $1.4M | $23.8M | ||
| Q1 25 | $257.0K | $23.1M | ||
| Q4 24 | $977.0K | $20.9M | ||
| Q3 24 | $660.0K | $20.3M | ||
| Q2 24 | $736.0K | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $12.3M | $7.4M | ||
| Q3 25 | $-8.6M | $9.3M | ||
| Q2 25 | $-6.9M | $8.0M | ||
| Q1 25 | $-5.4M | $7.8M | ||
| Q4 24 | — | $7.1M | ||
| Q3 24 | $-2.8M | $6.0M | ||
| Q2 24 | $-14.5M | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | 56.3% | 39.6% | ||
| Q3 25 | -2516.5% | 45.8% | ||
| Q2 25 | -701.0% | 43.4% | ||
| Q1 25 | -3350.2% | 43.4% | ||
| Q4 24 | — | 30.9% | ||
| Q3 24 | -1563.6% | 36.6% | ||
| Q2 24 | -1255.0% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | 65.7% | 30.7% | ||
| Q3 25 | -2572.2% | 37.3% | ||
| Q2 25 | -504.8% | 33.5% | ||
| Q1 25 | -2097.7% | 34.0% | ||
| Q4 24 | — | 34.0% | ||
| Q3 24 | -425.5% | 29.3% | ||
| Q2 24 | -1964.4% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $0.25 | $0.44 | ||
| Q3 25 | $-0.17 | $0.55 | ||
| Q2 25 | $-0.14 | $0.47 | ||
| Q1 25 | $-0.11 | $0.46 | ||
| Q4 24 | — | $0.41 | ||
| Q3 24 | $-0.06 | $0.35 | ||
| Q2 24 | $-0.30 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $270.7M |
| Total Assets | $59.0M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $40.0M | $471.1M | ||
| Q3 25 | $37.9M | $232.9M | ||
| Q2 25 | $44.8M | $345.2M | ||
| Q1 25 | $40.6M | — | ||
| Q4 24 | $59.3M | $243.5M | ||
| Q3 24 | $68.8M | — | ||
| Q2 24 | $73.0M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $49.4M | $266.0M | ||
| Q3 25 | $36.4M | $255.1M | ||
| Q2 25 | $44.5M | $240.9M | ||
| Q1 25 | $50.5M | $237.9M | ||
| Q4 24 | $55.1M | $227.9M | ||
| Q3 24 | $58.5M | $235.4M | ||
| Q2 24 | $60.4M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $59.0M | $4.1B | ||
| Q3 25 | $51.1M | $4.0B | ||
| Q2 25 | $60.7M | $4.1B | ||
| Q1 25 | $67.9M | $4.0B | ||
| Q4 24 | $90.6M | $4.0B | ||
| Q3 24 | $99.0M | $4.0B | ||
| Q2 24 | $107.8M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $12.9M |
| Free Cash FlowOCF − Capex | — | $12.4M |
| FCF MarginFCF / Revenue | — | 46.0% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | 1.50× | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $18.4M | $46.5M | ||
| Q3 25 | $-8.7M | $11.4M | ||
| Q2 25 | $-7.5M | $13.5M | ||
| Q1 25 | $-7.5M | $9.7M | ||
| Q4 24 | $-24.0M | $39.8M | ||
| Q3 24 | $765.0K | $12.9M | ||
| Q2 24 | $-10.9M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | — | $43.2M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | — | 178.3% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 53.6% | ||
| Q1 25 | — | 35.7% | ||
| Q4 24 | — | 65.6% | ||
| Q3 24 | — | 34.2% | ||
| Q2 24 | — | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | — | 125.3% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | — | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | 1.50× | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
WTBA
Segment breakdown not available.
